Highlights ZYUS Life Sciences Corporation

Equities

ZYUS

CA9899601095

Delayed Toronto S.E. Other stock markets 12:06:05 2024-07-12 pm EDT			5-day change	1st Jan Change
1.04 ^CAD	+2.97%		+0.97%	+15.56%

Jun. 04	ZYUS Life Sciences Corp. Brief: Says Cannabis Drug License Enables It to Expand its Clinical Research Activities by Manufacturing Drugs Containing Cannabis in Canada	MT
Jun. 04	ZYUS Life Sciences Corp. Brief: Lost 4.6% on Monday, But Today Said It Received Cannabis Drug License from Health Canada	MT

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

ZYUS Life Sciences Corp. Brief: Says Cannabis Drug License Enables It to Expand its Clinical Research Activities by Manufacturing Drugs Containing Cannabis in Canada	Jun. 04	MT
ZYUS Life Sciences Corp. Brief: Lost 4.6% on Monday, But Today Said It Received Cannabis Drug License from Health Canada	Jun. 04	MT
ZYUS Life Sciences Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 29	CI
ZYUS Life Sciences Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	May. 07	CI
ZYUS Life Sciences Receives US Patent for Pain Management Drug Candidate	Apr. 23	MT
Calian Group and MDA Brief: Calian Says "Strengthens Nuclear Capability" with Acquisition of MDA Ltd. Nuclear Assets	Mar. 05	MT
Calian Group Says Won Contract to Support Clinical Trial for ZYUS Life Sciences' Lead Drug Product Candidate	Feb. 20	MT
Calian Group Brief: Says Won Contract to Support Clinical Trial for ZYUS Life Sciences' Lead Drug Product Candidate	Feb. 20	MT
ZYUS Life Sciences Corp. Announces Phase 2 Trial Evaluating Trichomylin Softgel Capsules for Advanced Cancer Pain Care	Dec. 05	MT
ZYUS Life Sciences Corporation Announces Phase 2 Clinical Trial Evaluating Trichomylin®? Softgel Capsules for Advanced Cancer Pain Management	Dec. 05	CI
ZYUS Life Sciences Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 29	CI
ZYUS Life Sciences Corp. Brief: Announced "Positive" Phase I Clinical Trial Results for Trichomylin Softgels	Nov. 21	MT
ZYUS Life Sciences Corporation Announces Positive Phase I Clinical Trial Results for Trichomylin® Softgels	Nov. 21	CI
ZYUS Life Sciences Inc. completed the acquisition of Phoenix Canada Oil Company Limited in a reverse merger transaction.	23-06-08	CI
Phoenix Canada Oil Completes C$20.13-Milion Subscription Receipt Placement Ahead of Reverse Takeover	23-06-06	MT
Phoenix Canada Oil Company Limited Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-29	CI
Phoenix Canada Oil Company Limited Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-23	CI
Phoenix Canada Oil Company Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-28	CI
Phoenix Canada Oil Company Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-18	CI
Phoenix Canada, ZYUS Life Sciences Sign Letter of Intent for Reverse Takeover Transaction	22-05-30	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights ZYUS Life Sciences Corporation

Equities

ZYUS

CA9899601095

Highlights

Filters